NYSE: EWEdwards Lifesciences Corp Stock
$76.04+0.91 (+1.21%)
Updated Apr 25, 2025
EW Price
$76.04
Fair Value Price
N/A
Market Cap
$44.70B
52 Week Low
$58.93
52 Week High
$95.25
P/E
10.89x
P/B
4.47x
P/S
8.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.44B
Earnings
$4.17B
Gross Margin
79.5%
Operating Margin
79.91%
Profit Margin
76.7%
Debt to Equity
0.3
Operating Cash Flow
$542M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EW Overview
Edwards Lifesciences Corporation, a medical technology company, specializes in artificial heart valves and hemodynamic monitoring. Its products include surgical valves, transcatheter heart valves, and transcatheter mitral and tricuspid therapies. The company originated the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. Edwards was founded in 1958 and is headquartered in Irvine, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EW's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
EW
Ranked#45 of 104
Ranked#45 of 104
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $23.06 | A | |
| $14.58 | A |
Be the first to know about important EW news, forecast changes, insider trades & much more!
EW News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EW is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EW is good value based on its earnings relative to its share price (10.89x), compared to the US market average (29.65x)
P/E vs Market Valuation
EW is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more EW due diligence checks available for Premium users.
Valuation
EW price to earnings (PE)
For valuing profitable companies with steady earnings
Company
10.89x
Industry
37.18x
Market
29.65x
EW is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EW is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
EW price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.47x
Industry
3.92x
EW is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EW's financial health
Profit margin
Revenue
$1.4B
Net Income
$385.6M
Profit Margin
27.8%
EW's Earnings (EBIT) of $4.35B... subscribe to Premium to read more.
Interest Coverage Financials
EW's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.1B
Liabilities
$3.0B
Debt to equity
0.3
EW's short-term assets ($6.29B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EW's short-term assets ($6.29B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EW's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$127.5M
Investing
-$576.7M
Financing
$28.6M
EW's operating cash flow ($542.30M)... subscribe to Premium to read more.
Debt Coverage Financials
EW vs Medical Device Stocks
Edwards Lifesciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.